StockData
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. (TRDA) stock

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$5.03+0.07 (+1.41%)

Close on Nov 18, 2026Market cap $195.85MP/E –Yield –

Entrada Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Entrada Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$134.35M. For fiscal 2025 it was -$129.55M. The highest annual figure on record is $134.19M in fiscal 2023.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$129.55M–
FY2024Dec 31, 2024-$44.72M-133.3%
FY2023Dec 31, 2023$134.19M–
FY2022Dec 31, 2022-$96.67M–
FY2021Dec 31, 2021-$55.44M–
FY2020Dec 31, 2020-$27.89M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$32.47M–
Q1 FY2026Mar 31, 2026-$41.74M–
Q4 FY2025Dec 31, 2025-$32.00M–
Q3 FY2025Sep 30, 2025-$28.14M–
Q2 FY2025Jun 30, 2025-$29.76M-176.7%
Q1 FY2025Mar 31, 2025-$39.65M–
Q4 FY2024Dec 31, 2024-$32.24M–
Q3 FY2024Sep 30, 2024-$24.91M–
Q2 FY2024Jun 30, 2024$38.79M–
Q1 FY2024Mar 31, 2024-$26.36M-113.1%
Q4 FY2023Dec 31, 2023-$4.99M–
Q3 FY2023Sep 30, 2023-$25.94M–
Q2 FY2023Jun 30, 2023-$36.61M–
Q1 FY2023Mar 31, 2023$201.73M–
Q4 FY2022Dec 31, 2022-$28.01M–
Q3 FY2022Sep 30, 2022-$28.29M–
Q2 FY2022Jun 30, 2022-$18.78M–
Q1 FY2022Mar 31, 2022-$21.59M–
Q4 FY2021Dec 31, 2021-$21.86M–
Q3 FY2021Sep 30, 2021-$14.88M–
Q2 FY2021Jun 30, 2021-$9.45M–
Q1 FY2021Mar 31, 2021-$9.24M–
Q4 FY2020Dec 31, 2020-$8.07M–

More Entrada Therapeutics figures

See a number that looks wrong?